Sierra Oncology Inc (NASDAQ:SRRA) held an investor meeting on 27 February 2018, which provided a comprehensive update on its programs. The most immediately impactful data was a favourable safety profile reported from the ongoing Phase I/II clinical trials (monotherapy and gemcitabine combination). It was announced that the monotherapy trial had entered the Phase II dose-expansion portion of the trial and that the combination study will enter this phase in Q218. Preliminary results for this trial are expected in Q418.
SRA737 safety largely in line with expectations
The safety data for the two ongoing SRA737 trials largely showed an adverse events (AEs) profile similar to other drugs of its class (including gastrointestinal and hematological), albeit less severe (predominantly Grade 1 and 2). The monotherapy trial had one heart failure serious AE that could not be ruled out as drug related, but we do not consider this concerning in isolation. The current safety profile is attractive compared to other Chk1 inhibitors in development, and we will monitor whether it can be maintained through the expansion cohorts.
To read the entire report Please click on the pdf File Below: